Literature DB >> 23021729

Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma.

Cai-neng Cao1, Jing-wei Luo, Li Gao, Jun-lin Yi, Xiao-dong Huang, Kai Wang, Shi-ping Zhang, Yuan Qu, Su-yan Li, Wei-Ming Cai, Jian-ping Xiao, Zhong Zhang, Guo-zhen Xu.   

Abstract

The goal of this study is to study and report the clinical outcomes and patterns of failure after intensity-modulated radiotherapy (IMRT) for T4 nasopharyngeal carcinoma (NPC). A total of 70 patients treated with IMRT between 2004 and 2009 were eligible for study inclusion. According to the staging system of 2010 AJCC, all the primary tumors were attributed to T4 stage, while the distribution of disease by N stage was N0 in 2, N1 in 23, N2 in 39, N3a in 1, and N3b in 5. The location and extent of locoregional failures were transferred to the pretreatment planning computed tomography for dosimetry analysis. The median follow-up period was 26.8 (range, 4-78) months. The overall 2-year local failure-free survival, regional failure-free survival, distant failure-free survival, and overall survival rate was 82.1%, 92.3%, 73.8%, and 82.5%, respectively. Thirty-three patients had developed treatment failure. Of the 33 patients, 11, 2, and 15 had developed local failure, regional failure, and distant metastasis, respectively, 2 had developed locoregional failure, 1 had developed distant metastasis and failure at the primary, and 2 had developed distant metastasis and failure at the primary and nodal site. Eight of the locoregional failures were marginal. The results of treating T4 NPC with IMRT were excellent. Advanced T4 disease remained difficult to treat. One possible strategy is to lessen the dose constraint criteria of selected neurologic structures. Distant metastasis remains the most difficult treatment challenge for patients with T4 NPC at present, and more effective systemic chemotherapy should be explored.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23021729     DOI: 10.1016/j.oraloncology.2012.08.013

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  28 in total

1.  Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis.

Authors:  Shao-xuan Hu; Xiao-hui He; Mei Dong; Bo Jia; Sheng-yu Zhou; Jian-liang Yang; Sheng Yang; Chang-Gong Zhang; Peng Liu; Yan Qin; Lin Gui
Journal:  Med Oncol       Date:  2015-07-29       Impact factor: 3.064

2.  Analysis of the efficacy of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma with involvement of the cervical spine.

Authors:  Hao Jiang; Gengming Wang; Hongwei Song; Hongbo Xu; Yajun Zhang; Yufu Zhou; Hanfei Cai; Shimiao Duan
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

3.  Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.

Authors:  Zhaodong Fei; Ting Xu; Xiufang Qiu; Mengying Li; Taojun Chen; Li Li; Chaoxiong Huang; Chuanben Chen
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-03       Impact factor: 4.553

4.  A prediction model for xerostomia in locoregionally advanced nasopharyngeal carcinoma patients receiving radical radiotherapy.

Authors:  Minying Li; Jingjing Zhang; Yawen Zha; Yani Li; Bingshuang Hu; Siming Zheng; Jiaxiong Zhou
Journal:  BMC Oral Health       Date:  2022-06-17       Impact factor: 3.747

5.  Nasopharyngeal carcinoma with intracranial extension in the era of intensity-modulated radiotherapy: case-control study using propensity score matching method.

Authors:  Cai-Neng Cao; Jing-Wei Luo; Li Gao; Guo-Zhen Xu; Jun-Lin Yi; Xiao-Dong Huang; Su-Yan Li; Jian-Ping Xiao; Zhong Zhang
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-08-18       Impact factor: 2.503

6.  Sp1 is over-expressed in nasopharyngeal cancer and is a poor prognostic indicator for patients receiving radiotherapy.

Authors:  Jun Wang; Min Kang; Yu-Tao Qin; Zhu-Xin Wei; Jing-Jian Xiao; Ren-Sheng Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

7.  Preliminary results of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a retrospective study of 364 patients.

Authors:  Fangfang Kong; Hongmei Ying; Shuang Huang; Chengrun Du; Junjun Zhou; Chaosu Hu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-18       Impact factor: 2.503

8.  Intensity-modulated radiotherapy for stage IVA/IVB nasopharyngeal carcinoma: clinical outcomes and patterns of failure in an endemic area in China.

Authors:  Lei Zeng; Yun-Ming Tian; Xue-Ming Sun; Ying Huang; Chun-Yan Chen; Fei Han; Shuai Liu; Mei Lan; Ying Guan; Xiao-Wu Deng; Tai-Xiang Lu
Journal:  Strahlenther Onkol       Date:  2014-05-17       Impact factor: 3.621

9.  Outcomes of patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.

Authors:  Shyh-An Yeh; Tzer-Zen Hwang; Chih-Chun Wang; Chuen-Chien Yang; Ching-Feng Lien; Chien-Chung Wang; Tun-Yen Hsu; Ruey-Feng Hsu; Yu-Chen Shih; Yaw-Chang Huang; Meng-Che Hsieh; Jhy-Shyan Gau; Liyun Chang; Tsair-Fwu Lee
Journal:  J Radiat Res       Date:  2021-05-12       Impact factor: 2.724

10.  The impact of reduced-volume, intensity-modulated radiation therapy on disease control in nasopharyngeal carcinoma.

Authors:  Yu-Wei Lin; Chia-Chun Chen; Li-Ching Lin; Steve P Lee
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.